Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials

Abstract

4055 Background: 5 randomized phase II and III trials have yet investigated the role of oxaliplatin in combination with either capecitabine (XELOX/CAPOX) or infusional 5-FU. The aim of these studies was to show non-inferiority of the oral versus the infusional combination. This meta-analysis was performed to compare the efficacy of capecitabine/oxaliplatin compared with infusional 5-fluorouracil (5- FU)/oxaliplatin regimens. Methods: This meta-analysis was based on all published summary data from reported randomized [phase II-III] trials comparing XELOX/CAPOX versus different infusional 5-FU/oxaliplatin. In total 2,575 patients (5-FU: 1,278 pts, capecitabine 1,297 pts) were included and analyzed for response rates (RR), progression free and overall survival (PFS, OS) (fixed effect & random effects models). The required estimates and standard deviations were derived from the published RR, hazard ratios (HR) and their confidence intervals (CI) or logrank p values, respectively. Results: With the exception o...